Published in Nat Rev Cardiol on December 10, 2015
Anti-fibrotic actions of relaxin. Br J Pharmacol (2016) 0.76
Atrial Electrophysiological Remodeling and Fibrillation in Heart Failure. Clin Med Insights Cardiol (2016) 0.75
Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. Korean Circ J (2017) 0.75
High molecular weight fibroblast growth factor-2 as a promising prognostic biomarker to predict the occurrence of heart failure in atrial fibrillation patients. Heart Vessels (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 14.70
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 11.63
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Trends in heart failure incidence and survival in a community-based population. JAMA (2004) 8.90
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation (1995) 8.62
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
The burden and costs of chronic diseases in low-income and middle-income countries. Lancet (2007) 8.33
Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 8.18
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol (1998) 6.76
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 6.58
Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation (2001) 6.29
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol (2008) 5.71
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet (1994) 5.37
Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med (1997) 5.25
Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med (2004) 4.99
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med (2001) 4.81
Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med (2013) 4.79
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation (2013) 4.60
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
The epidemiology of heart failure. Eur Heart J (1997) 4.31
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Clinical epidemiology of heart failure. Heart (2007) 4.11
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med (2012) 3.96
Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol (2001) 3.83
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med (1995) 3.56
Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J (2004) 3.52
Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J (2012) 3.52
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA (2014) 3.50
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Amiodarone and the risk of cancer: a nationwide population-based study. Cancer (2013) 3.32
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol (2010) 3.24
Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J (1999) 3.18
Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet (1994) 3.18
Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol (2014) 3.09
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (2015) 3.02
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation (1995) 2.88
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol (2003) 2.73
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
The epidemiologic transition: a theory of the epidemiology of population change. 1971. Milbank Q (2005) 2.63
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart (2004) 2.56
In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation (2013) 2.56
Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med (1999) 2.54
Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation (2010) 2.47
Calcium cycling in congestive heart failure. J Mol Cell Cardiol (2002) 2.46
Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol (2012) 2.40
Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol (2008) 2.37
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 2.31
Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc (2013) 2.28
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 2.27
Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol (2000) 2.25
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol (2014) 2.21